BR112012015916A2 - derivados de pirazina e seu uso no tratamento de distúrbios neurológicos - Google Patents

derivados de pirazina e seu uso no tratamento de distúrbios neurológicos

Info

Publication number
BR112012015916A2
BR112012015916A2 BR112012015916A BR112012015916A BR112012015916A2 BR 112012015916 A2 BR112012015916 A2 BR 112012015916A2 BR 112012015916 A BR112012015916 A BR 112012015916A BR 112012015916 A BR112012015916 A BR 112012015916A BR 112012015916 A2 BR112012015916 A2 BR 112012015916A2
Authority
BR
Brazil
Prior art keywords
treatment
neurological disorders
pyrazine derivatives
pyrazine
derivatives
Prior art date
Application number
BR112012015916A
Other languages
English (en)
Portuguese (pt)
Inventor
Tintelnot-Blomley Marina
Jacob Veenstra Siem
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43598456&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012015916(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112012015916A2 publication Critical patent/BR112012015916A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR112012015916A 2009-12-31 2010-12-22 derivados de pirazina e seu uso no tratamento de distúrbios neurológicos BR112012015916A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29172409P 2009-12-31 2009-12-31
PCT/EP2010/070502 WO2011080176A1 (en) 2009-12-31 2010-12-22 Pyrazine derivatives and their use in the treatment of neurological disorders

Publications (1)

Publication Number Publication Date
BR112012015916A2 true BR112012015916A2 (pt) 2017-04-25

Family

ID=43598456

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012015916A BR112012015916A2 (pt) 2009-12-31 2010-12-22 derivados de pirazina e seu uso no tratamento de distúrbios neurológicos

Country Status (27)

Country Link
US (2) US20120277244A1 (enExample)
EP (1) EP2519515B1 (enExample)
JP (1) JP5600754B2 (enExample)
KR (1) KR101419157B1 (enExample)
CN (1) CN102712621B (enExample)
AU (1) AU2010338365B2 (enExample)
BR (1) BR112012015916A2 (enExample)
CA (1) CA2785341A1 (enExample)
CL (1) CL2012001762A1 (enExample)
CR (1) CR20120332A (enExample)
CU (1) CU20120099A7 (enExample)
EA (1) EA201200952A1 (enExample)
EC (1) ECSP12012065A (enExample)
ES (1) ES2445536T3 (enExample)
GT (1) GT201200219A (enExample)
HN (1) HN2012001413A (enExample)
IL (1) IL220268A0 (enExample)
MX (1) MX2012007754A (enExample)
NZ (1) NZ600136A (enExample)
PE (1) PE20121640A1 (enExample)
PH (1) PH12012501007A1 (enExample)
PL (1) PL2519515T3 (enExample)
PT (1) PT2519515E (enExample)
SG (1) SG181431A1 (enExample)
TN (1) TN2012000249A1 (enExample)
WO (1) WO2011080176A1 (enExample)
ZA (1) ZA201203614B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101052122B1 (ko) 2005-10-25 2011-07-26 시오노기세야쿠 가부시키가이샤 아미노디히드로티아진 유도체
EP2147914B1 (en) 2007-04-24 2014-06-04 Shionogi&Co., Ltd. Aminodihydrothiazine derivatives substituted with cyclic groups
EP2151435A4 (en) 2007-04-24 2011-09-14 Shionogi & Co PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE
MX2010013256A (es) 2008-06-13 2010-12-21 Shionogi & Co Derivado heterociclico que contiene azufre que tiene actividad inhibitoria de beta-secretasa.
JPWO2010047372A1 (ja) 2008-10-22 2012-03-22 塩野義製薬株式会社 Bace1阻害活性を有する2−アミノピリミジン−4−オンおよび2−アミノピリジン誘導体
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
JPWO2011071135A1 (ja) 2009-12-11 2013-04-22 塩野義製薬株式会社 オキサジン誘導体
EA201291366A1 (ru) * 2010-06-09 2013-04-30 Янссен Фармацевтика Нв Производные 5-амино-3,6-дигидро-1h-пиразин-2-она в качестве ингибиторов бета-секретазы (bace)
EA021240B1 (ru) 2010-06-09 2015-05-29 Янссен Фармацевтика Нв Производные 5,6-дигидро-2h-[1,4]оксазин-3-иламина в качестве ингибиторов бета-секретазы (bace)
EP2585440A1 (en) * 2010-06-28 2013-05-01 Janssen Pharmaceutica, N.V. 3-amino-5,6-dihydro-1h-pyrazin-2-one derivatives useful for the treatement of alzheimer's disease and other forms of dementia
CA2816285A1 (en) 2010-10-29 2012-05-03 Shionogi & Co., Ltd. Naphthyridine derivative
EP2634188A4 (en) 2010-10-29 2014-05-07 Shionogi & Co FUSIONED AMINODIHYDROPYRIMIDINE DERIVATIVE
US9840507B2 (en) 2010-12-22 2017-12-12 Janssen Pharmaceutica, Nv 5,6-dihydro-imidazo[1,2-a]pyrazin-8-ylamine derivatives useful as inhibitors of beta-secretase (BACE)
US8524897B2 (en) 2011-01-12 2013-09-03 Novartis Ag Crystalline oxazine derivative
CN106117193B (zh) 2011-01-13 2019-09-13 诺华股份有限公司 新的杂环衍生物及其在神经性疾病治疗中的应用
EP2663308A1 (en) * 2011-01-13 2013-11-20 Novartis AG Bace-2 inhibitors for the treatment of metabolic disorders
HUE026338T2 (en) 2011-03-01 2016-05-30 Janssen Pharmaceutica Nv 6,7-dihydro-pyrazolo[1,5-a]pyrazin-4-ylamine derivatives useful as inhibitors of beta-secretase (bace)
MX340031B (es) 2011-03-09 2016-06-21 Janssen Pharmaceutica Nv Derivados de 3,4-dihidropirrolo[1,2-a]pirazin-1-ilamina utiles como inhibidores de beta-secretasa (bace).
US9221839B2 (en) 2011-04-07 2015-12-29 Merck Sharp & Dohme Corp. C5-C6 oxacyclic-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
US9145426B2 (en) 2011-04-07 2015-09-29 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
MX2013011947A (es) 2011-04-13 2014-01-16 Merck Sharp & Dohme Iminotiazinas 5-sustituidas y sus monoxidos y dioxidos como inhibidores de la enzima que encinde la proteina precursora amiloide en el sitio beta, composiciones y su uso.
TW201247635A (en) 2011-04-26 2012-12-01 Shionogi & Co Oxazine derivatives and a pharmaceutical composition for inhibiting BAC1 containing them
EP2747769B1 (en) 2011-08-22 2017-08-02 Merck Sharp & Dohme Corp. 2-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use
US8338413B1 (en) 2012-03-07 2012-12-25 Novartis Ag Oxazine derivatives and their use in the treatment of neurological disorders
JP2016501827A (ja) 2012-10-24 2016-01-21 塩野義製薬株式会社 Bace1阻害作用を有するジヒドロオキサジンまたはオキサゼピン誘導体
EP2934539B1 (en) 2012-12-20 2019-03-27 Merck Sharp & Dohme Corp. C5, c6 oxacyclic-fused iminothiazine dioxide compounds as bace inhibitors
ES2721073T3 (es) 2013-06-12 2019-07-26 Janssen Pharmaceutica Nv Derivados de 4-amino-6-fenil-6,7-dihidro[1,2,3]triazolo[1,5 a]pirazina como inhibidores de beta-secretasa (BACE)
CA2911690C (en) 2013-06-12 2021-08-24 Janssen Pharmaceutica Nv 4-amino-6-phenyl-5,6-dihydroimidazo[1,5-a]pyrazine derivatives as inhibitors of beta-secretase (bace)
MX368326B (es) 2013-06-12 2019-09-27 Janssen Pharmaceutica Nv Derivados de 4-amino-6-fenil-5,6-dihidroimidazo[1,5-a]pirazin-3(2h )-ona como inhibidores de beta-secretasa (bace).
AU2015367594C1 (en) 2014-12-18 2019-10-31 Janssen Pharmaceutica Nv 2,3,4,5-tetrahydropyridin-6-amine and 3,4-dihydro-2H-pyrrol-5-amine compound inhibitors of beta-secretase
CN107011134B (zh) * 2017-04-28 2021-02-05 浙江中欣氟材股份有限公司 一种2-氟-5-溴苯乙酮的合成方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6911868A (enExample) 1968-08-31 1970-03-03
AUPQ319899A0 (en) * 1999-10-01 1999-10-28 Fujisawa Pharmaceutical Co., Ltd. Amide compounds
WO2002060492A1 (en) * 2001-01-30 2002-08-08 Cytopia Pty Ltd Methods of inhibiting kinases
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
EP1702919B1 (en) 2003-12-29 2012-05-30 Msd K.K. Novel 2-heteroaryl-substituted benzimidazole derivative
US20050215884A1 (en) * 2004-02-27 2005-09-29 Greicius Michael D Evaluation of Alzheimer's disease using an independent component analysis of an individual's resting-state functional MRI
KR101052122B1 (ko) * 2005-10-25 2011-07-26 시오노기세야쿠 가부시키가이샤 아미노디히드로티아진 유도체
EP2395002B1 (en) * 2005-11-08 2014-06-18 Vertex Pharmaceuticals Inc. Pharmaceutical composition containing a heterocyclic modulator of atp-binding cassette transporters.
JP2010514689A (ja) * 2006-12-22 2010-05-06 ノバルティス アーゲー 癌、炎症およびウイルス感染症の処置のためのcdk阻害剤としてのヘテロアリール−ヘテロアリール化合物
US20100317850A1 (en) 2008-01-18 2010-12-16 Yuichi Suzuki Condensed aminodihydrothiazine derivative
JPWO2010047372A1 (ja) 2008-10-22 2012-03-22 塩野義製薬株式会社 Bace1阻害活性を有する2−アミノピリミジン−4−オンおよび2−アミノピリジン誘導体
AR077328A1 (es) * 2009-07-24 2011-08-17 Novartis Ag Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos
EA201291366A1 (ru) * 2010-06-09 2013-04-30 Янссен Фармацевтика Нв Производные 5-амино-3,6-дигидро-1h-пиразин-2-она в качестве ингибиторов бета-секретазы (bace)
EP2585440A1 (en) * 2010-06-28 2013-05-01 Janssen Pharmaceutica, N.V. 3-amino-5,6-dihydro-1h-pyrazin-2-one derivatives useful for the treatement of alzheimer's disease and other forms of dementia

Also Published As

Publication number Publication date
NZ600136A (en) 2013-09-27
HN2012001413A (es) 2015-03-23
JP2013516395A (ja) 2013-05-13
EP2519515A1 (en) 2012-11-07
PT2519515E (pt) 2014-02-17
CN102712621B (zh) 2015-03-11
HK1172023A1 (en) 2013-04-12
ECSP12012065A (es) 2012-08-31
ES2445536T3 (es) 2014-03-03
TN2012000249A1 (en) 2013-12-12
MX2012007754A (es) 2012-08-01
IL220268A0 (en) 2012-07-31
US20120277244A1 (en) 2012-11-01
WO2011080176A1 (en) 2011-07-07
US20150322038A1 (en) 2015-11-12
CU20120099A7 (es) 2012-07-31
ZA201203614B (en) 2013-01-30
EP2519515B1 (en) 2013-11-06
JP5600754B2 (ja) 2014-10-01
CL2012001762A1 (es) 2012-12-21
CA2785341A1 (en) 2011-07-07
AU2010338365A1 (en) 2012-06-07
KR101419157B1 (ko) 2014-07-11
PL2519515T3 (pl) 2014-04-30
KR20120102795A (ko) 2012-09-18
SG181431A1 (en) 2012-07-30
EA201200952A1 (ru) 2013-02-28
CN102712621A (zh) 2012-10-03
GT201200219A (es) 2013-10-10
PE20121640A1 (es) 2012-12-17
PH12012501007A1 (en) 2013-01-14
AU2010338365B2 (en) 2014-01-30
CR20120332A (es) 2012-07-12

Similar Documents

Publication Publication Date Title
BR112012015916A2 (pt) derivados de pirazina e seu uso no tratamento de distúrbios neurológicos
BR112013017779A2 (pt) derivados de oxazina e seu uso no tratamento de distúrbios neurológicos
CO6491058A2 (es) Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurológicos
EA201490888A1 (ru) Новые производные пурина и их применение для лечения заболевания
EA201200176A1 (ru) Производные оксазина и их применение для лечения неврологических нарушений
BR112014008045A2 (pt) benzilindazóis substituídos para uso como inibidores de bub1 cinase no tratamento de doenças hiperproliferativas
BR112014005468A2 (pt) derivados de aminopiridina para uso como moduladores de atividade quinase
BR112015025354A2 (pt) compostos di-hidropirido-pirimidínicos como inibidores de autotaxina
DK2150530T3 (da) Substituerede sulfonamid-derivater
EA201391106A1 (ru) Новые гетероциклические производные
BR112014001880A2 (pt) derivados de carboxamida e ureia contendo pirazol heteroaromáticos substituídos como ligantes de receptor vaniloide
BR112013000059A2 (pt) derivados de piperidina e seus usos para o tratamento de distúrbios metabólicos
BR112013031098A2 (pt) halogeno-alquil-1,3 oxazinas como inibidores de bace1 e/ou bace2
BR112015026023A2 (pt) derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1
BR112014018341A8 (pt) Compostos aza-heterocíclicos
BR112014001908A2 (pt) derivados aza heterocíclicos substituídos
ECSP11010992A (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), producción y uso de los mismos como productos medicinales
BR112012032721A2 (pt) compostos heterocíclicos, sua preparação e sua aplicação terapêutica
BR112014028813A2 (pt) 5-amino[1,4]tiazinas como inibidores bace1
BR112015001207A8 (pt) derivados de carbamato/ureia, seus usos, composição farmacêutica, forma livre e seu método de preparação
BR112015007823A2 (pt) derivados de ácido hialurônico modificado e uso dos mesmos
BR112015010223A2 (pt) compostos tricíclicos para o uso no tratamento e/ou controle de obesidade
BR112012014463A2 (pt) ativadores de glucoquinase azaindol
BR112016007430A2 (pt) 5-aril-1-imino-1-oxo-[1,2,4]tiadiazinas
BR112015003281A8 (pt) derivados de diazepinona úteis para tratamento de síndrome x frágil, doença de parkinson ou por refluxo, seus usos, composição farmacêutica, e combinação

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]